Maze Therapeutics, Inc. Common Stock MAZE
Analyst Ratings
- Consensus
- Buy — 8 Buy · 0 Hold · 0 Sell (8 analysts)
- Avg. Price Target
- $68.25 (+140.5% upside)
Key Stats
- Today's Range
- $24.50 – $29.40
- 50-Day Range
- $21.95 – $30.80
- 52-Week Range
- $12.81 – $53.65
- Volume
- 3.57 million shs
- Average Volume
- 581K shs
- Market Cap
- $1.24 billion
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 2.74
- Price / Sales
- 62.19
Short Interest
- Short Interest
- 2.15%
- Days to Cover
- 3.01
Financials (TTM)
- Revenue
- $20.00 million
- Net Income
- $-133,590,000
- Net Margin
- -667.95%
- Return on Equity
- -29.48%
- Debt-to-Equity
- 0.09
About Maze Therapeutics, Inc. Common Stock
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
Related Stocks
Compare head-to-head: MAZE vs AMGN·MAZE vs MRNA·MAZE vs HALO·MAZE vs TWST
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.